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OBJECTIVE — Heterozygous, gain-of-function mutations of the insulin gene can cause per-
manentdiabeteswithonsetrangingfromtheneonatalperiodthroughadulthood.Theaimofour
study was to screen for the insulin gene in patients who had been clinically classiﬁed as type 1
diabetic but who tested negative for type 1 diabetes autoantibodies.
RESEARCH DESIGN AND METHODS — We reviewed the clinical records of 326
patientswiththediagnosisoftype1diabetesandidentiﬁedsevenprobandswhohaddiabetesin
isolation and were negative for ﬁve type 1 diabetes autoantibodies. We sequenced the INS gene
in these seven patients.
RESULTS — In two patients whose diabetes onset had been at 2 years 10 months of age and
at 6 years 8 months of age, respectively, we identiﬁed the mutation G
B8S and a novel mutation
in the preproinsulin signal peptide (A
Signal23S).
CONCLUSIONS — Insulingenemutationsarerareinabsolutetermsinpatientsclassiﬁedas
type 1 diabetic (0.6%) but can be identiﬁed after a thorough screening of type 1 diabetes
autoantibodies.
Diabetes Care 32:123–125, 2009
M
utationsof the insulin(INS)gene
associated with neonatal- and
infancy-onset diabetes cause
sustained stress of the endoplasmic re-
ticulum, which in turn triggers apopto-
sis of the pancreatic -cell (1). In
patients with insulin mutations with
proteotoxic effect, diabetes presents in
isolation and the onset of hyperglyce-
miamayoccurwelloutsidetheneonatal
period (1–4). As a consequence, indi-
vidualswithINSgenemutationsmaybe
confused with patients having autoim-
mune type 1 diabetes (1–4).
RESEARCH DESIGN AND
METHODS— We reviewed the clini-
cal records of 326 patients with the diag-
nosis of diabetes (age range at diagnosis
1–18 years), each consecutively referred
to the pediatric diabetes clinic at San Raf-
faele Hospital during the years 2003–
2006. Among these 326, we identiﬁed 24
patients who were negative for all the
common type 1 diabetes autoantibodies
(islet cell antibody [ICA], GAD antibody
[GADA], IA-2 antigen [IA-2A], and insu-
lin antibody [IAA]) at the time of diagno-
sis. The cutoffs (in arbitrary units) were
GADA 3, IA-2A 1, and IAA 5; the
threshold for positivity in each assay cor-
responds with 99th percentiles of 200
control subjects with normal glucose tol-
erance. From the 24 patients negative for
autoantibodies, we excluded 4 patients
with adolescent type 2 diabetes (Table 1).
Among the remaining 20 patients, we se-
lected those with diabetes in isolation,
who were tested for the novel type 1 dia-
betesautoantibodyagainstZntransporter
8 (ZnT8A; cutoff in arbitrary units 12)
(5). Seven patients who were negative for
all antibodies were analyzed for insulin
gene mutations by DNA direct sequenc-
ing, along with four ZnT8A
 patients
(control subjects). When appropriate,
mutations found were designated accord-
ing to their position in the mature insulin
chains (1).
RESULTS— In two patients, we de-
tected a heterozygous missense mutation
of the INS gene: the already described
G
B8S (or G32S) (2,3) and a novel muta-
tion resulting in a serine for an alanine in
the 23rd amino acid of the preproinsulin
molecule A
Signal23S. Both mutations were
conﬁrmed by digestion with the appro-
priate restriction enzyme. DNA sequenc-
ing of the INS gene of the probands’
parents showed a normal sequence (i.e.,
the mutations arose as spontaneous mu-
tations). No mutation was found in 200
control subjects with normal glucose tol-
erance or in the ZnT8A
 patients.
ThechildwiththeG
B8Smutationwas
born after an uneventful pregnancy (39
weeks of gestation) with a birth weight of
2,770 g (10th centile). At onset of diabe-
tes,hewas2years10monthsoldandlean
(BMI 16 kg/m
2, 25th centile for corre-
sponding age) and showed a detectable
C-peptide (0.49 ng/ml) that was low, but
still measurable 2 years after diagnosis
(0.34 ng/ml). Presently, he is 6 years old,
hisinsulindoseis0.7units kg
1 day
1,
and his A1C is 8.7% (normal reference
6%).
The individual with the A
Signal23S
mutation (birth weight 3,350 g, 25–50th
centile) presented with typical symptoms
of diabetes (polyuria and polydipsia)
when he was 6 years 8 months old (A1C
11% at diabetes onset). He was lean (BMI
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2, 50th centile). Insulin was
started and continued for 6 months; dur-
ingthefollowing2years,thepatientwent
off and on insulin several times (a pattern
that may resemble the so-called honey-
moon phase of type 1 diabetes). His C-
peptide levels, measured 11 and 24
months after onset of hyperglycemia,
were1.32and0.7ng/ml,respectively.He
is now 10 years old, his insulin dose is
0.17 units   kg
1   day
1, and his A1C is
6.4%.
CONCLUSIONS — Previously, het-
erozygous INS gene mutations had been
detected in adult patients with so-called
familial hyperinsulinemia or hyperproin-
sulinemia who presented with variable
phenotypes (mild diabetes or even hypo-
glycemia) and high serum levels of radio-
immunoassayableinsulinorproinsulin-like
material.Morerecently,INSmutationshave
beenfoundtobeassociatedwithneonatal-
and infancy-onset diabetes (1–3). We
demonstrated that mutant insulins with
proteotoxic effect cannot be secreted
when expressed in HEK 293 cell line (1),
and it is likely that S
B8 and S
Signal23 are
also retained in the endoplasmic reticu-
lum.Nevertheless,thepatientbearingthe
mutation in the signal peptide shows a
milder clinical course, and we cannot ex-
clude that S
Signal23 preproinsulin may be
partially processed and secreted. Present
knowledge indicates that insulin muta-
tions with a proteotoxic effect cause apo-
ptosis of the pancreatic -cell (1), a
process that in most patients takes several
months after birth (1–3) or, in some indi-
viduals, years (1–4 and this report). Of
note, only six patients among those re-
portedinthearticlesbyStøyetal.,Edghill
et al., Molven et al., and Colombo et al.
(1–4) were diagnosed within the ﬁrst 4
weeks of birth (i.e., the time interval still
inusetodeﬁnetheneonatalperiod);most
ofthem(morethan40)werediagnosedin
the ﬁrst year of life (infancy). Thus, we
believe that classifying these patients as
having permanent neonatal diabetes is
misleading and that this term should be
abandoned in favor of the term “mono-
genic diabetes of infancy,” as previously
suggested by our group (1). Indeed, at
least 12 patients with insulin gene muta-
tions had the diagnosis of diabetes during
childhood or adulthood (1–4 and this
report), making the neonatal onset an
exception.
The Italian proband bearing the G
B8S
(G32S) mutation had the diagnosis of di-
abetes at 3 years of age, 2 years later
T
a
b
l
e
1
—
C
l
i
n
i
c
a
l
c
r
i
t
e
r
i
a
u
s
e
d
f
o
r
c
l
a
s
s
i
ﬁ
c
a
t
i
o
n
o
f
n
e
w
c
a
s
e
s
o
f
d
i
a
b
e
t
e
s
w
i
t
h
o
n
s
e
t
d
u
r
i
n
g
c
h
i
l
d
h
o
o
d
o
r
a
d
o
l
e
s
c
e
n
c
e
T
y
p
e
1
d
i
a
b
e
t
e
s
T
y
p
e
2
d
i
a
b
e
t
e
s
M
o
n
o
g
e
n
i
c
d
i
a
b
e
t
e
s
i
n
i
s
o
l
a
t
i
o
n
H
N
F
1
-

(
M
O
D
Y
5
)
W
o
l
f
r
a
m
s
y
n
d
r
o
m
e
P
o
s
t
-
C
M
V
i
n
f
e
c
t
i
o
n
n
3
0
9
4
7
2
3
1
T
y
p
e
1
d
i
a
b
e
t
e
s
a
u
t
o
a
n
t
i
b
o
d
i
e
s
(
I
C
A
,
G
A
D
A
,
I
A
-
2
A
,
I
A
A
,
Z
n
T
8
)
*

1
0
0
0
0
0
B
M
I
N
o
t
c
o
n
s
i
d
e
r
e
d

9
0
t
h
c
e
n
t
i
l
e
N
o
r
m
a
l
,
l
o
w
N
o
r
m
a
l
,
l
o
w
N
o
r
m
a
l
,
l
o
w
N
o
r
m
a
l
,
l
o
w
C
-
p
e
p
t
i
d
e
(
n
g
/
m
l
)
L
o
w
,
u
n
d
e
t
e
c
t
a
b
l
e

1
.
5
†
L
o
w
,
n
o
r
m
a
l
,
h
i
g
h

1
.
5

1
.
5

1
.
5
A
g
e
r
a
n
g
e
a
t
d
i
a
g
n
o
s
i
s
o
f
d
i
a
b
e
t
e
s
1
–
1
8
y
e
a
r
s
1
2
–
1
5
y
e
a
r
s
2
y
e
a
r
s
7
m
o
n
t
h
s
–
1
5
y
e
a
r
s
4
m
o
n
t
h
s
1
2
–
1
4
y
e
a
r
s
1
0
–
1
4
y
e
a
r
s
1
3
y
e
a
r
s
F
e
a
t
u
r
e
s
o
t
h
e
r
t
h
a
n
d
i
a
b
e
t
e
s
N
o
n
e
H
y
p
e
r
t
e
n
s
i
o
n
,
d
i
s
l
i
p
i
d
e
m
i
a
N
o
n
e
R
e
n
a
l
d
i
s
e
a
s
e
,
p
a
n
c
r
e
a
s
h
y
p
o
p
l
a
s
i
a
a
t
u
l
t
r
a
s
o
u
n
d
o
r
N
M
R
,
a
b
n
o
r
m
a
l
l
i
v
e
r
e
n
z
y
m
e
s
O
p
t
i
c
a
t
r
o
p
h
y
,
d
i
a
b
e
t
e
s
i
n
s
i
p
i
d
u
s
,
d
e
a
f
n
e
s
s
D
o
c
u
m
e
n
t
e
d
p
e
r
i
n
a
t
a
l
C
M
V
i
n
f
e
c
t
i
o
n
,
g
r
o
w
t
h
r
e
t
a
r
d
a
t
i
o
n
,
d
e
a
f
n
e
s
s
*
F
o
u
r
p
a
t
i
e
n
t
s
w
e
r
e
n
e
g
a
t
i
v
e
f
o
r
I
C
A
,
G
A
D
A
,
I
A
-
2
A
,
a
n
d
I
A
A
b
u
t
p
o
s
i
t
i
v
e
f
o
r
Z
n
T
8
A
.
†
A
t
l
e
a
s
t
t
w
o
d
e
t
e
r
m
i
n
a
t
i
o
n
s
6
m
o
n
t
h
s
a
p
a
r
t
.
C
M
V
,
c
y
t
o
m
e
g
a
l
o
v
i
r
u
s
;
M
O
D
Y
,
m
a
t
u
r
i
t
y
o
n
s
e
t
d
i
a
b
e
t
e
s
o
f
t
h
e
y
o
u
n
g
;
N
M
R
,
n
u
c
l
e
a
r
m
a
g
n
e
t
i
c
r
e
s
o
n
a
n
c
e
.
Insulin mutations in children with diabetes
124 DIABETES CARE, VOLUME 32, NUMBER 1, JANUARY 2009than patients carrying the same mutation
asdescribedbyStøyetal.(2).Presently,it
is not clear why patients with the same
INS gene mutation, even from the same
family, can present with diabetes during
infancy, childhood, or adulthood (1–4).
It is tempting to speculate that the apo-
ptotic process in some of these patients
may be modulated or slowed by the indi-
vidual’s capacity to degrade misfolded in-
sulin(byaprocessknownasendoplasmic
reticulum–associated degradation). An-
other intriguing hypothesis, not mutually
exclusive with the previous one, could be
that -cell regeneration may take place in
some individuals and not in others. The
observation that in these two patients
(and in others previously described) (1)
insulin secretion was still detectable 2
years after onset of diabetes suggests that
either of these mechanisms could be at
work.
Inconclusion,insulingenemutations
are rare in absolute terms among patients
clinically classiﬁed as type 1 diabetic (2 of
326 or 0.6%) but can be identiﬁed after a
thorough screening of type 1 diabetes
autoantibodies.
Acknowledgments— No potential conﬂicts
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